Biotech News

Prime Medicine to Present at Goldman Sachs 47th Annual Global Healthcare Conference

Prime Medicine (PRME)Prime MedicineConference / presentation

CAMBRIDGE, Mass., June 03, 2026 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that Allan Reine, M.D., Chief Executive Officer of Prime Medicine, will

Open original release

Related news

Prime Medicine

Prime Medicine is a gene-editing company focused on prime-editing technology for a broad set of genetic diseases. The platform aims to expand the precision and flexibility of genome editing.

Recent company news

Stock data

Close
3.01 USD
Market cap
579.78M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States